Skip to Content

Ruxolitinib Side Effects

In Summary

Commonly reported side effects of ruxolitinib include: anemia, dizziness, equilibrium disturbance, headache, labyrinthitis, meniere's disease, neutropenia, thrombocytopenia, vertigo, and orthostatic dizziness. Other side effects include: weight gain, and flatulence. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to ruxolitinib: oral tablet

Along with its needed effects, ruxolitinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ruxolitinib:

More Common

  • Black, tarry stools
  • bladder pain
  • bleeding gums
  • blood in the urine or stools
  • bruising
  • chills
  • cloudy urine
  • collection of blood under the skin
  • cough
  • deep, dark purple bruise
  • difficult, burning, or painful urination
  • fever
  • frequent urge to urinate
  • itching, pain, redness, or swelling
  • large, flat, blue or purplish patches in the skin
  • lower back or side pain
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pus in the urine
  • shortness of breath
  • small, red or purple spots on the skin
  • sore throat
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Less Common

  • Painful blisters on the trunk of the body

Some side effects of ruxolitinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Bloated or full feeling
  • dizziness or lightheadedness
  • excess air or gas in the stomach or intestines
  • feeling of constant movement of self or surroundings
  • headache
  • passing gas
  • sensation of spinning
  • weight gain

For Healthcare Professionals

Applies to ruxolitinib: oral tablet

Dermatologic

Very common (10% or more): Bruising (up to 23.2%)

Common (1% to 10%): Herpes zoster[Ref]

Gastrointestinal

Common (1% to 10%): Flatulence, gastrointestinal bleeding[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (up to 14.4%)[Ref]

Hematologic

Very common (10% or more): Anemia (up to 96.1%), thrombocytopenia (up to 69.8%), neutropenia (up to 18.7%)[Ref]

Immunologic

Common (1% to 10%): Tuberculosis

Frequency not reported: Progressive multifocal leukoencephalopathy[Ref]

Metabolic

Very common (10% or more): Hypercholesterolemia (up to 17.4%), weight gain (up to 10%)[Ref]

Nervous system

Very common (10% or more): Dizziness (up to 18.1%), headache (up to 14.8%)

Common (1% to 10%): Intracranial bleeding[Ref]

General

The most common adverse reactions were anemia, thrombocytopenia, bruising, dizziness, and headache.[Ref]

Cardiovascular

Very common (10% or more): Bleeding (up to 32.6%)[Ref]

Hepatic

Very common (10% or more): ALT increased (up to 27.1%), AST increased (up to 19.3%)[Ref]

References

1. "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide